NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $187.96 -3.23 (-1.69%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$186.56▼$191.6650-Day Range$187.98▼$245.2952-Week Range$161.65▼$275.00Volume526,484 shsAverage Volume588,406 shsMarket Capitalization$9.68 billionP/E Ratio22.11Dividend YieldN/APrice Target$231.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Charles River Laboratories International alerts: Email Address Charles River Laboratories International MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside22.9% Upside$231.00 Price TargetShort InterestHealthy3.07% of Shares Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.18Based on 12 Articles This WeekInsider TradingN/AProj. Earnings Growth9.28%From $10.02 to $10.95 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.71 out of 5 starsMedical Sector50th out of 910 stocksCommercial Physical Research Industry3rd out of 11 stocks 3.1 Analyst's Opinion Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 4 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.07% of the outstanding shares of Charles River Laboratories International have been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently decreased by 14.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCharles River Laboratories International has received a 76.18% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Charles River Laboratories International is -0.55. Previous Next 1.8 News and Social Media Coverage News SentimentCharles River Laboratories International has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Charles River Laboratories International this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 9.28% in the coming year, from $10.02 to $10.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 22.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 22.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 3.97. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Charles River Laboratories International's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.>> Get Your FREE Wealth Protection Guide << About Charles River Laboratories International Stock (NYSE:CRL)Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.Read More CRL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRL Stock News HeadlinesSeptember 3, 2024 | americanbankingnews.comCharles River Laboratories International, Inc. to Post Q3 2024 Earnings of $2.44 Per Share, Zacks Research Forecasts (NYSE:CRL)September 1, 2024 | finance.yahoo.comCalculating The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 31, 2024 | americanbankingnews.comQ1 2025 EPS Estimates for Charles River Laboratories International, Inc. (NYSE:CRL) Cut by Zacks ResearchAugust 28, 2024 | insidermonkey.comCharles River Laboratories International (CRL) Fell Due to a More Cautious Funding EnvironmentAugust 22, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesAugust 14, 2024 | markets.businessinsider.comHold Rating on Charles River Labs Amidst Pharma Restructuring and Uncertain Near-Term EarningsAugust 13, 2024 | globenewswire.comCHARLES RIVER ALERT: Bragar Eagel & Squire, P.C. is Investigating Charles River Laboratories International, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 8, 2024 | benzinga.comCritical Insights From Charles River Analyst Ratings: What You Need To KnowAugust 8, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on Charles River Labs (CRL)August 8, 2024 | msn.comCharles River Laboratories International, Inc. (NYSE:CRL) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | bizjournals.comCharles River Labs says it's cutting staff amid ‘headwinds’August 7, 2024 | reuters.comCharles River cuts 2024 forecast as funding crunch among biotech clients persistsAugust 7, 2024 | msn.comCharles River Labs Plummets 17% On 'Bleaker' Expectations For 2024August 7, 2024 | investopedia.comCharles River Labs Says It Expects Sales To Fall, Sending Its Stock TumblingJuly 24, 2024 | finance.yahoo.comCharles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug DiscoveryJuly 16, 2024 | globenewswire.comCRL INVESTIGATION ALERT: Johnson Fistel LLP Investigates Charles River Laboratories' Directors and Officers for Breach of Fiduciary DutiesSee More Headlines Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Commercial physical research Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CUSIP15986410 CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees21,800Year Founded1947Price Target and Rating Average Stock Price Target$231.00 High Stock Price Target$290.00 Low Stock Price Target$191.00 Potential Upside/Downside+22.9%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$8.50 Trailing P/E Ratio22.11 Forward P/E Ratio18.76 P/E Growth3.97Net Income$474.62 million Net Margins10.83% Pretax Margin13.25% Return on Equity14.96% Return on Assets6.70% Debt Debt-to-Equity Ratio0.65 Current Ratio1.58 Quick Ratio1.21 Sales & Book Value Annual Sales$4.08 billion Price / Sales2.37 Cash Flow$15.97 per share Price / Cash Flow11.77 Book Value$72.19 per share Price / Book2.60Miscellaneous Outstanding Shares51,510,000Free Float50,840,000Market Cap$9.68 billion OptionableOptionable Beta1.36 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. James C. Foster J.D. (Age 73)CEO, President & Chairman Comp: $2.66MMs. Flavia H. Pease (Age 51)Corporate Executive VP & CFO Comp: $1.66MMs. Birgit Girshick (Age 54)Corporate Executive VP & COO Comp: $1.28MMr. Joseph W. LaPlume (Age 50)Corporate Executive Vice President of Corporate Development & Strategy Comp: $928.36kMr. William D. Barbo (Age 63)Corporate Executive Vice President of Community Relations Comp: $1MMr. Michael Gunnar Knell (Age 47)Corporate Senior VP & Chief Accounting Officer Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerMr. Mark MintzCorporate Senior VP & Chief Information OfficerTodd SpencerCorporate Vice President of Investor RelationsMr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerMore ExecutivesKey CompetitorsMettler-Toledo InternationalNYSE:MTDIlluminaNASDAQ:ILMNWatersNYSE:WATBio-TechneNASDAQ:TECHBrukerNASDAQ:BRKRView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 23,672 shares on 9/5/2024Ownership: 0.046%Clearbridge Investments LLCSold 144,633 shares on 8/27/2024Ownership: 2.657%Cetera Investment AdvisersBought 229 shares on 8/22/2024Ownership: 0.019%Truist Financial CorpSold 2,761 shares on 8/21/2024Ownership: 0.072%Northwestern Mutual Wealth Management Co.Bought 6,011 shares on 8/16/2024Ownership: 0.098%View All Insider TransactionsView All Institutional Transactions CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $236.40 at the beginning of the year. Since then, CRL shares have decreased by 20.5% and is now trading at $187.96. View the best growth stocks for 2024 here. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) issued its earnings results on Wednesday, August, 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.39 by $0.41. The medical research company earned $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Charles River Laboratories International had a net margin of 10.83% and a trailing twelve-month return on equity of 14.96%. Is Charles River Laboratories International buying back stock? Charles River Laboratories International's Board of Directors initiated a share buyback program on Wednesday, August 7th 2024, which allows the company to repurchase $1,000,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 9.6% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its shares are undervalued. What is James C. Foster's approval rating as Charles River Laboratories International's CEO? 291 employees have rated Charles River Laboratories International Chief Executive Officer James C. Foster on Glassdoor.com. James C. Foster has an approval rating of 75% among the company's employees. Does Charles River Laboratories International have any subsidiaries? Charles River Laboratories International subsidiaries include Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and more. Who are Charles River Laboratories International's major shareholders? Charles River Laboratories International's top institutional investors include Kayne Anderson Rudnick Investment Management LLC (3.71%), Clearbridge Investments LLC (2.66%), Allspring Global Investments Holdings LLC (2.43%) and Earnest Partners LLC (1.95%). Insiders that own company stock include James C Foster, Birgit Girshick, Joseph W Laplume, William D Barbo, Victoria L Creamer, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Richard F Wallman. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Boeing (BA), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA), Salesforce (CRM) and Abbott Laboratories (ABT). This page (NYSE:CRL) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.